Intraoperative magnetic resonance imaging for ablation of hepatic tumors.

Surg Endosc

Department of Surgery, Division of Surgical Oncology and Center for Advanced Surgical Technologies (CAST) of Norton Hospital, University of Louisville School of Medicine, Louisville, Kentucky 40292, USA.

Published: October 2006

Background: The most significant rise in the use of hepatic ablation has come from image-guided techniques with both computed tomography (CT) and ultrasound (US). The recent development of open-configuration magnetic resonance scanners has opened up an entire new area of image-guided surgical and interventional procedures. Thus the aim of this study was to evaluate the use of intraoperative MRI (iMRI) ablation of hepatic tumors performed by surgeons.

Method: Percutaneous iMRI hepatic ablation was performed from January 2003 to February 2005 for control of either primary or secondary hepatic disease.

Results: Eighteen hepatic ablations were performed on 11 patients with a median age of 71 (range: 51-81) years for metastatic colorectal cancer (n = 6), hepatocellular cancer (n = 2), cholangiocarcinoma (n = 2), and metastatic neuroendocrine (n = 1). Median hospital stay was 1 day, with complications occurring in 2 patients. After a median follow up of 18 months, there have been no local ablation recurrences, 5 patients are free of disease, 4 are alive with disease, 1 has died of disease, and 1 has died of other causes.

Conclusions: Image-guided hepatic ablations represent a useful technique in managing hepatic tumors. Intraoperative MRI represents a new technique with initial success that has been limited to European centers. Further evaluation in U.S. centers has demonstrated iMRI to be useful for certain hepatic tumors that cannot be adequately visualized by US or CT.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00464-005-0496-8DOI Listing

Publication Analysis

Top Keywords

hepatic tumors
16
hepatic
9
magnetic resonance
8
ablation hepatic
8
hepatic ablation
8
intraoperative mri
8
imri hepatic
8
hepatic ablations
8
patients median
8
disease died
8

Similar Publications

Objective: To develop a predictive model for microvascular invasion (MVI) in hepatocellular carcinoma (HCC) through radiomics analysis, integrating data from both enhanced computed tomography (CT) and magnetic resonance imaging (MRI).

Methods: A retrospective analysis was conducted on 93 HCC patients who underwent partial hepatectomy. The gold standard for MVI was based on the histopathological diagnosis of the tissue.

View Article and Find Full Text PDF

Background: Hepatocellular carcinoma (HCC), the most common form of liver cancer, has a significant mortality rate, largely due to late diagnosis. Recent advances in medical research have demonstrated the potential of biomarkers for early detection. Moreover, the discovery and use of prognostic biomarkers offer a ray of hope in the fight against liver cancer.

View Article and Find Full Text PDF

Background: Helicobacter pylori bacteria colonize the gastric mucosa and contribute to the occurrence and development of gastrointestinal diseases. According to the WHO, H. pylori bacteria are considered class I carcinogen.

View Article and Find Full Text PDF

Interleukin-17A and Interleukin-17F Gene Polymorphisms in Egyptian Patients with Chronic Hepatitis C and Hepatocellular Carcinoma.

Asian Pac J Cancer Prev

January 2025

Department of Biochemistry, Biotechnology Research Institute, High Throughput Molecular and Genetic laboratory, Center for Excellences for Advanced Sciences, National Research Centre, Dokki, Giza, Egypt.

Objective: Interleukin IL-17A and IL-17F are critical cytokines involved in inflammatory processes. Genetic variations in IL-17A and IL-17F might be linked to chronic hepatitis C (CHC) and an increased risk of hepatocellular carcinoma (HCC), a cancer associated with long-term inflammation. This study aims to examine the relationship between specific polymorphisms in IL-17A (rs2275913) and IL-17F (rs763780) and their association with HCV-related HCC in an Egyptian population.

View Article and Find Full Text PDF

Accelerated Endosomal Escape of Splice-Switching Oligonucleotides Enables Efficient Hepatic Splice Correction.

ACS Appl Mater Interfaces

January 2025

Faculty of Life Sciences, Department of Pharmaceutical Sciences, Laboratory of Macromolecular Cancer Therapeutics (MMCT), University of Vienna, Josef-Holaubek-Platz 2, 1090 Vienna, Austria.

Splice-switching oligonucleotides (SSOs) can restore protein functionality in pathologies and are promising tools for manipulating the RNA-splicing machinery. Delivery vectors can considerably improve SSO functionality in vivo and allow dose reduction, thereby addressing the challenges of RNA-targeted therapeutics. Here, we report a biocompatible SSO nanocarrier, based on redox-responsive disulfide cross-linked low-molecular-weight linear polyethylenimine (cLPEI), for overcoming multiple biological barriers from subcellular compartments to en-route serum stability and finally in vivo delivery challenges.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!